Immunogenic oncolysis by tigilanol tiglate

Jonathan G. Pol; Manuela Lizarralde-Guerrero; Guido Kroemer

doi:10.1080/2162402X.2024.2360230

Immunogenic oncolysis by tigilanol tiglate

Jonathan G. Pol, Manuela Lizarralde-Guerrero, Guido Kroemer

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

langue originale	Anglais
Numéro d'article	2360230
journal	OncoImmunology
Volume	13
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2024.2360230
état	Publié - 1 janv. 2024

Accès au document

10.1080/2162402X.2024.2360230

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d9fd8358b37b47498d7411ea8de9ba34,

title = "Immunogenic oncolysis by tigilanol tiglate",

abstract = "Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.",

keywords = "Cancer immunosurveillance, immunogenic cell death, intratumor immunotherapy, oncolysis, tigilanol tiglate",

author = "Pol, {Jonathan G.} and Manuela Lizarralde-Guerrero and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1080/2162402X.2024.2360230",

language = "English",

volume = "13",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Immunogenic oncolysis by tigilanol tiglate

AU - Pol, Jonathan G.

AU - Lizarralde-Guerrero, Manuela

AU - Kroemer, Guido

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

AB - Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

KW - Cancer immunosurveillance

KW - immunogenic cell death

KW - intratumor immunotherapy

KW - oncolysis

KW - tigilanol tiglate

UR - http://www.scopus.com/inward/record.url?scp=85194880585&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2024.2360230

DO - 10.1080/2162402X.2024.2360230

M3 - Comment/debate

C2 - 38812571

AN - SCOPUS:85194880585

SN - 2162-4011

VL - 13

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2360230

ER -